USPTO Approves All 10 PTAB Reviews Amid Heightened Pharmaceutical Patent Scrutiny
In a move that underscores the increasing activity within the pharmaceutical intellectual property space, U.S. Patent and Trademark Office Director John Squires has instituted ten new Patent Trial and Appeal Board (PTAB) reviews. Notably, none of the 10 petitions were rejected, highlighting the critical scrutiny and evolving dynamics within patent litigation and review processes. These…